SEC Form 4 · accession 0001209191-17-066810
Adamas Pharmaceuticals Inc · ADMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jennifer J Rhodes
Officer — CBO, GC & Compliance Officer
Period of report
Dec 21, 2017
Accepted (ET)
Dec 21, 2017 · 4:43 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001328143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Dec 21, 2017 | S | 440 | $32.30 | D | 28,860 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units.
- F2Includes 845 shares purchased on 11/30/17 through the issuer's employee stock purchase plan.